Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biophytis ADR Representing 4000 Ord Shs BPTSY

Healthcare Biotechnology
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory... see more

Recent & Breaking News (OTCPK:BPTSY)

Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021

Accesswire October 29, 2021

Biophytis to Restate Previously Issued Financial Statements

GlobeNewswire October 6, 2021

Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

GlobeNewswire October 6, 2021

Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

GlobeNewswire October 4, 2021

Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 - October 2, 2021

GlobeNewswire October 4, 2021

Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 - October 2, 2021

GlobeNewswire September 29, 2021

Biophytis Reports H1 2021 Financial Results and Provides Business Update

GlobeNewswire September 17, 2021

Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19

GlobeNewswire September 15, 2021

Biophytis to Attend Key Upcoming Investor Events and Industry Conferences

GlobeNewswire September 14, 2021

Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment

GlobeNewswire September 9, 2021

Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19

GlobeNewswire August 16, 2021

Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021

GlobeNewswire August 13, 2021

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

GlobeNewswire August 2, 2021

Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice

GlobeNewswire July 19, 2021

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

GlobeNewswire July 12, 2021

Biophytis Reinforces Leadership Teams with Three Senior Appointments

GlobeNewswire July 8, 2021

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

GlobeNewswire June 30, 2021

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

GlobeNewswire June 30, 2021

Biophytis announces new convertible bond financing for up to Euro32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for Euro6 million

GlobeNewswire June 18, 2021

BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

GlobeNewswire May 12, 2021